This was a rapid review of TA514, which gave a resounding “no”. Bayer came back with a more generous PAS and a submission that used the Committee’s preferred assumption. The ERG undertook some further analyses which allowed the Committee to conclude, rightly or wrongly, that the most plausible ICER is below £50,000 per QALY gained.
ScHARR-TAG were the ERG and the additional analyses were undertaken by Matt Stevenson, Paul Tappenden and Andrew Rawdin. Further details are available here.
